Sleep Medications: A Clinical Review Across Generations

1. A Brief History of Sleep Medications

The history of pharmaceutical sleep aids mirrors broader trends in medicine: initial enthusiasm and widespread adoption, followed by growing recognition of dependence, toxicity, and long-term risk, culminating in the search for mechanistically safer alternatives. Each generation of sleep medications has been marketed as an improvement over its predecessor — a claim that has proved partially true with each iteration.

2. Classes, Mechanisms, and Pharmacology

Barbiturates (Historical)

Barbiturates act as positive allosteric modulators of GABA-A receptors at a distinct binding site from benzodiazepines. At therapeutic doses they enhance chloride conductance; at supratherapeutic doses they can directly activate the receptor independent of GABA, accounting for their capacity to produce fatal respiratory depression. They are potent inducers of CYP1A2, CYP2C9, and CYP3A4 — a source of numerous drug interactions. Phenobarbital retains clinical use for seizure disorders and alcohol withdrawal; amobarbital is occasionally used in narcoanalysis. No barbiturate carries a current FDA indication for routine insomnia given the availability of safer alternatives.

Benzodiazepines

Benzodiazepines act as full agonists at the BZD binding site of GABA-A receptors (the alpha/gamma subunit interface), enhancing the frequency of chloride channel opening in the presence of GABA. They produce hypnotic, anxiolytic, anticonvulsant, and muscle-relaxant effects, with relative selectivity depending on receptor subunit composition across brain regions. Hypnotic benzodiazepines include temazepam (intermediate half-life 8–20 h), triazolam (short half-life 1.5–5 h), and flurazepam (long half-life including active metabolite desalkylflurazepam: 40–250 h). Tolerance develops to sedative effects within days to weeks; physical dependence and withdrawal can be severe, including seizures.

Z-Drugs (Non-Benzodiazepine GABA-A PAMs)

Zolpidem, zaleplon, and eszopiclone bind to the same BZD site on GABA-A receptors. Initial pharmacological studies suggested preferential binding to alpha-1 containing receptors (associated with sedation) over alpha-2/3 subunits (associated with anxiolysis and muscle relaxation), leading to marketing claims of improved selectivity. In clinical practice, this selectivity is incomplete and dose-dependent. Tolerance, dependence, and rebound insomnia occur at rates comparable to traditional benzodiazepines. Complex sleep behaviors including sleepwalking, sleep-driving, and sleep-eating represent rare but potentially life-threatening adverse effects; the FDA issued a black box warning in 2019 and contraindicated these agents in patients who have previously experienced such episodes.

Pharmacokinetic profiles vary: zolpidem IR (half-life 2.5 h), eszopiclone (half-life 6 h, longer in elderly), zaleplon (half-life 1 h, shortest of the class). The FDA reduced recommended zolpidem doses in 2013, particularly for women (5 mg IR; 6.25 mg CR), due to next-morning blood concentration data demonstrating impaired driving performance.

Melatonin Receptor Agonists

Ramelteon (Rozerem) is a selective agonist at MT1 and MT2 receptors. MT1 receptor activation suppresses neuronal firing in the suprachiasmatic nucleus (SCN), promoting sleep onset; MT2 receptor activation phase-shifts circadian rhythms. Ramelteon has high affinity for MT1/MT2 and negligible affinity for GABA-A, dopamine, histamine, or opioid receptors, accounting for its lack of abuse potential, physical dependence, or scheduled status. Peak plasma concentration occurs approximately 45 minutes after administration; half-life is 1–2.6 hours, with active metabolite M-II contributing additional activity. Fluvoxamine markedly increases ramelteon exposure via CYP1A2 inhibition and is contraindicated.

Dual Orexin Receptor Antagonists (DORAs)

Orexin (hypocretin) neuropeptides — orexin-A and orexin-B — are produced in the lateral hypothalamus and project broadly to arousal-promoting nuclei including the locus coeruleus, raphe nuclei, tuberomammillary nucleus, and basal forebrain. They act as potent wake-promoting signals through OX1R and OX2R. DORAs competitively block both receptors, reducing the drive to wakefulness rather than globally suppressing CNS activity. This mechanism preserves sleep architecture (including REM sleep), avoids respiratory depression, and does not produce physical dependence or tolerance. Suvorexant (10–20 mg), lemborexant (5–10 mg), and daridorexant (25–50 mg) are approved DORAs in the US. Daridorexant demonstrated in the HERALD phase 3 trial the first pharmacological insomnia data showing improvement in patient-reported daytime functioning.

Sedating Antidepressants Used Off-Label

Trazodone (SARI — serotonin antagonist and reuptake inhibitor) is the most widely prescribed off-label sleep medication in the United States. Its sedative properties derive from potent 5-HT2A and H1 antagonism; it is not a scheduled substance and carries minimal abuse potential. Trazodone lacks robust RCT evidence for chronic insomnia but is widely used due to familiarity, safety profile, and dual utility in comorbid depression. Doxepin 3–6 mg (Silenor) is FDA-approved specifically for sleep maintenance insomnia; at these doses, pharmacological activity is limited almost entirely to H1 blockade, distinct from antidepressant doses. Mirtazapine produces sedation predominantly through H1 blockade, enhanced at low doses (7.5–15 mg) due to autoreceptor considerations; metabolic effects limit long-term utility for pure insomnia.

Antihistamines (OTC)

Diphenhydramine (Benadryl, ZzzQuil) and doxylamine (Unisom) are the active ingredients in most OTC sleep aids. H1 receptor blockade in the cortex and subcortical arousal nuclei produces sedation. Rapid tolerance develops within 3–4 days, severely limiting efficacy for sustained use. Anticholinergic effects (dry mouth, urinary retention, constipation, tachycardia, confusion) are clinically significant, particularly in older adults. These agents appear on the AGS Beers Criteria and are not recommended for chronic insomnia management in any population.

Low-Dose Quetiapine (Off-Label)

Quetiapine at doses of 12.5–100 mg is commonly prescribed off-label for insomnia, particularly in psychiatric inpatient and outpatient settings. At low doses, H1 blockade dominates the pharmacological profile; dopamine D2 and alpha-1 adrenergic antagonism become more prominent at higher doses. This off-label use is controversial: no FDA indication exists for insomnia, and the metabolic, extrapyramidal, and QTc risks of antipsychotic exposure apply even at low doses with chronic use. It is reasonable in patients with comorbid psychiatric conditions where quetiapine is otherwise indicated.

3. Evolving Indications and Clinical Opinions

The clinical landscape for sleep pharmacotherapy has shifted substantially over the past two decades, driven by a convergence of epidemiological data on long-term BZD/Z-drug harms, more rigorous clinical trial design, and the emergence of guideline-endorsed behavioral interventions.

CBT-I as the Foundation of Treatment

The American Academy of Sleep Medicine (AASM), American College of Physicians (ACP), and American College of Chest Physicians now uniformly endorse Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment for chronic insomnia disorder in adults. CBT-I components — sleep restriction, stimulus control, relaxation techniques, sleep hygiene, and cognitive restructuring — produce durable improvements in sleep onset latency, wake after sleep onset, and sleep efficiency that persist following treatment cessation. Pharmacotherapy is second-line, with the explicit recommendation that the shortest effective duration be used.

Regulatory Tightening of Z-Drugs

Following accumulation of case reports and post-marketing surveillance data, the FDA took several actions against Z-drugs. In 2013, recommended doses of zolpidem were reduced (5 mg for women, 10 mg for men; CR formulations reduced proportionally) based on next-morning blood concentration studies demonstrating driving impairment. In 2019, the FDA required a black box warning for all Z-drugs for complex sleep behaviors, and contraindicated use in patients who had previously experienced such episodes. These regulatory actions have meaningfully reduced Z-drug prescribing among clinicians who have updated their practice accordingly.

DORAs — Emerging as Preferred Agents

Growing clinical consensus favors DORAs for most patients requiring pharmacotherapy, based on their favorable dependence, respiratory, and cognitive safety profiles. Suvorexant was approved in 2014 at doses of 10–20 mg. Lemborexant (5–10 mg) demonstrated superiority to zolpidem CR in head-to-head trials on multiple sleep architecture parameters. Daridorexant (25–50 mg) is notable for the HERALD trial demonstrating statistically significant improvement in the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) — a patient-reported daytime function outcome — marking the first pharmacological insomnia therapy to show this benefit in a pivotal trial.

Specialized Applications

4. Side Effects Across Generations — Evolution and Shortcomings

Benzodiazepines and Z-Drugs

The burden of adverse effects from benzodiazepines and Z-drugs represents the central clinical problem driving the search for alternatives. Tolerance to sedative effects develops within days to weeks, requiring dose escalation to maintain efficacy. Physical dependence occurs with regular use beyond 2–4 weeks; discontinuation produces rebound insomnia (often worse than the original complaint) and withdrawal symptoms ranging from anxiety and tremor to seizures. Next-day psychomotor impairment — including driving impairment — is well documented, particularly with longer-acting agents and in elderly patients. Anterograde amnesia is a class effect. An association between chronic BZD use and dementia has been reported in multiple large observational studies, though causal inference remains contested due to confounding by indication.

Falls and hip fractures in elderly patients represent a major public health consequence of BZD/Z-drug prescribing. Meta-analyses consistently demonstrate approximately 40–50% increased risk of falls with hypnotic use in older adults. Z-drugs carry the additional specific risk of complex sleep behaviors, including sleep-driving — behaviors patients are typically amnestic for and that carry life-threatening risk.

Antihistamines

The anticholinergic profile of diphenhydramine and doxylamine produces dry mouth, urinary retention, constipation, tachycardia, blurred vision, and confusion. In older adults, these effects are compounded by age-related reductions in cholinergic reserve. The narrow-angle glaucoma and benign prostatic hyperplasia contraindications are clinically critical and frequently overlooked when patients self-select OTC agents. Tolerance to sedative effects develops within 3–4 days, leading to dose escalation and compounding anticholinergic burden.

Ramelteon

Ramelteon is notably well tolerated. The most commonly reported adverse effects are dizziness and somnolence, both at low rates. Prolactin elevation has been reported — clinically relevant if hyperprolactinemia is a concern. The primary pharmacokinetic risk is the CYP1A2 pathway: fluvoxamine (a potent CYP1A2 inhibitor) increases ramelteon AUC approximately 190-fold and is an absolute contraindication. Moderate CYP1A2 inhibitors (ciprofloxacin, fluvoxamine) require caution. CYP1A2 inducers (rifampin, omeprazole, smoking) reduce ramelteon exposure and may diminish efficacy.

Dual Orexin Receptor Antagonists

Next-day somnolence is the primary dose-dependent adverse effect of DORAs; it is more pronounced with higher doses and longer half-life agents (lemborexant). Unlike BZDs, DORAs do not produce respiratory depression in standard dosing and appear safe in patients with mild-to-moderate obstructive sleep apnea and COPD — a clinically significant advantage. Complex sleep behaviors have been reported rarely and are included in prescribing information; sleep paralysis has also been reported. Physical dependence does not occur. There is no evidence of abuse at clinical doses despite the Schedule IV classification. No meaningful cognitive impairment has been demonstrated on standardized testing at recommended doses.

Trazodone and Mirtazapine

Trazodone's most clinically relevant adverse effects are orthostatic hypotension (particularly in elderly patients or those on antihypertensives) and morning sedation at higher doses. Priapism, though rare (estimated 1 in 6,000–8,000 male patients), is a urological emergency requiring immediate intervention; patients should be counseled at initiation. Drug interactions via CYP3A4 and serotonin syndrome risk with concurrent serotonergic agents warrant attention. Mirtazapine's primary limitations for chronic insomnia use are weight gain (often 5–10 kg over months) and metabolic effects, making it better suited for patients with comorbid depression, poor appetite, or weight loss.

Low-Dose Quetiapine

Off-label use of quetiapine for insomnia exposes patients to antipsychotic class risks including metabolic syndrome (weight gain, dyslipidemia, glucose dysregulation), QTc prolongation, orthostatic hypotension, and — with chronic use — tardive dyskinesia risk (low but non-zero). Clinicians should document informed consent and clinical rationale when using quetiapine off-label for insomnia in the absence of a comorbid psychiatric indication.

Side Effect Profile Comparison

The following heatmap illustrates the relative clinical burden of six major adverse effect categories across eight commonly used sleep agents. Intensity reflects clinical significance based on published evidence and FDA labeling; cells are color-coded from low (pale) to high (dark) burden.

5. Choosing the Right Sleep Medication

Clinical selection of a sleep medication requires integration of insomnia subtype, patient age and comorbidities, substance use history, concurrent medications, and the strength of evidence for each agent. The framework below reflects current AASM and ACP guidance alongside the evolving evidence base.

Clinical Selection Flowchart

6. The Beers Criteria and High-Risk Populations

2023 AGS Beers Criteria

The 2023 American Geriatrics Society Beers Criteria explicitly lists all benzodiazepines and Z-drugs in the "avoid" category for older adults, regardless of duration or indication. The rationale encompasses: increased sensitivity to CNS depressant effects, impaired compensatory reflexes, and the well-documented association between these agents and falls, hip fractures, motor vehicle accidents, delirium, and hospitalization in this population.

The association between chronic BZD use and dementia risk has been the subject of multiple large observational studies and meta-analyses, with most showing a modest increased odds ratio (approximately 1.2–1.5). Causal inference is complicated by protopathic bias (insomnia and anxiety may represent prodromal dementia symptoms) and confounding by indication. However, given the absence of evidence for benefit with long-term use and the biological plausibility of cognitive effects via GABAergic disruption of hippocampal function, the precautionary principle argues against chronic BZD/Z-drug use.

Elderly Patients

Preferred agents for sleep in older adults per current evidence and guidelines: CBT-I (first-line), ramelteon 8 mg (safe, no dependence, non-scheduled), low-dose doxepin 3–6 mg (FDA-approved specifically for maintenance insomnia, not Beers-listed at these doses), and suvorexant 10–20 mg (limited geriatric-specific data but favorable mechanism). Lower starting doses are prudent for DORAs in elderly patients due to pharmacokinetic changes in hepatic clearance.

Pregnancy

Sleep disorders are common in pregnancy; management must balance maternal benefit against fetal risk. Benzodiazepines carry FDA category concerns and are associated with neonatal withdrawal syndromes. Z-drugs have limited human data. Melatonin lacks adequate human reproductive data. Doxylamine 10 mg + pyridoxine 10 mg (Diclegis/Bonjesta) is FDA-approved for nausea and vomiting in pregnancy; its sedating properties are sometimes used by clinicians for insomnia, though this is an off-label application. CBT-I is safe and should be the primary intervention in pregnant patients. Diphenhydramine has been used historically but anticholinergic concerns limit its utility. No sleep medication is clearly preferred in pregnancy; the risk-benefit discussion should be individualized.

Substance Use Disorder

Patients with current or past substance use disorder represent a high-risk population for BZD/Z-drug prescribing due to cross-tolerance and addiction transfer risk. DORAs (suvorexant, lemborexant, daridorexant) are the preferred pharmacological option: no abuse potential has been demonstrated clinically, they are Schedule IV based on precautionary scheduling rather than evidence of abuse, and they do not produce physical dependence. Ramelteon is unscheduled and carries no abuse potential whatsoever. Low-dose doxepin is another safe option. All scheduled sleep agents — including benzodiazepines and Z-drugs — should be avoided in patients with active substance use disorder or those in recovery, except in carefully considered, time-limited circumstances with close monitoring.

7. Routine Monitoring and Deprescribing

Principles of Short-Term Use

For all scheduled sleep agents (BZDs and Z-drugs), the guiding principle is to prescribe for the shortest effective duration, typically 2–4 weeks, with a clearly communicated plan for discontinuation from the time of initiation. Prescribing with no defined endpoint is the most common error in sleep pharmacology and the primary driver of long-term dependence. Unscheduled agents (ramelteon, doxepin 3–6 mg, DORAs) can be used for longer durations if clinically warranted, with reassessment of continued benefit at each visit.

Monitoring During Treatment

• Sleep diary: Prospective daily record of sleep onset, total sleep time, awakenings, and daytime function. More reliable than retrospective reporting. Recommended for all patients on sleep pharmacotherapy.
• Epworth Sleepiness Scale (ESS): Standardized 8-item questionnaire for daytime sleepiness. Score above 10 warrants investigation for sleep apnea as a primary or contributing etiology.
• PHQ-9: Comorbid depression is present in a substantial proportion of insomnia patients and often drives or perpetuates the sleep disorder. Routine screening facilitates appropriate dual-diagnosis management.
• Signs of dependence: Escalating dose requests, anxiety around anticipated missed doses, withdrawal symptoms between doses, and difficulty tapering are red flags requiring direct clinical discussion and a structured taper plan.
• Next-day impairment assessment: Particularly for DORAs and longer-acting agents; patients should be counseled not to drive until they know how the medication affects them the following morning.

Deprescribing BZDs and Z-Drugs

Deprescribing chronically used BZDs/Z-drugs is a clinical skill that requires patience, patient engagement, and systematic planning. Key principles:

• Slow taper is essential: Reductions of 10–25% of the current dose every 2 weeks are generally well tolerated. Faster tapers produce more severe withdrawal and have higher failure rates. Some patients require months-long tapers at very small dose reductions.
• Switch to longer half-life agent: Converting from a short-acting agent (triazolam, zolpidem) to a longer-acting benzodiazepine (diazepam) provides more stable blood levels, reducing peak withdrawal symptoms and facilitating a more gradual taper.
• CBT-I during taper: Concurrent CBT-I significantly improves taper success rates and reduces relapse. Addressing the underlying insomnia cognitions and behaviors is critical to long-term discontinuation.
• Manage expectations: Rebound insomnia is expected during the first 1–2 weeks of a taper and does not represent treatment failure. Patients should be counseled that this is temporary and normal.
• Gradual, flexible, patient-centered: Rigid fixed-interval tapers perform worse than flexible patient-guided approaches. Allow patients to pause the taper and stabilize if withdrawal is significant before proceeding.

8. References